Skip to main content
Figure 4 | Journal of Hematology & Oncology

Figure 4

From: Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells

Figure 4

JAK2 siRNA transfected K562 cells had increased sensitivity to imatinib. (A) K562 cells were transfected with JAK2 siRNA or a control siRNA. Cell lysates were analyzed by immunoblotting 72 h after transfection using Jak2 and β-actin Abs. Blots were scanned and optical densities were determined using the ImageJ system. (B) K562 and siRNA-transfected K562 cells were cultured at a concentration of 8 × 104/mL in the presence or absence of feeder cells. The cells were treated with 1 μM imatinib for 72 h. Viable cell numbers were calculated. Results are representative of three separate experiments. (C) K562 and siRNA-transfected K562 cells were treated with imatinib for 24 h, and total extracts were examined by immunoblotting using anti-phospho ABL, ABL, phospho-Crk-L, Crk-L, phospho-MAPK, Erk-1 and β-actin Abs. Blots were scanned and optical densities were determined using ImageJ software.

Back to article page